Advanced

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

Dimopoulos, M A; Leleu, X; Palumbo, A; Moreau, P; Delforge, M; Cavo, M; Ludwig, H; Morgan, G J; Davies, F E and Sonneveld, P, et al. (2014) In Leukemia 28(8). p.1573-1585
Abstract
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who... (More)
In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism are provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.Leukemia accepted article preview online, 5 February 2014; doi:10.1038/leu.2014.60. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia
volume
28
issue
8
pages
1573 - 1585
publisher
Nature Publishing Group
external identifiers
  • pmid:24496300
  • wos:000341334600001
  • scopus:84905695380
ISSN
1476-5551
DOI
10.1038/leu.2014.60
language
English
LU publication?
yes
id
13e2ab16-f6f3-4198-8d71-4634545433c0 (old id 4335623)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24496300?dopt=Abstract
date added to LUP
2014-03-06 21:23:37
date last changed
2017-10-01 03:23:48
@article{13e2ab16-f6f3-4198-8d71-4634545433c0,
  abstract     = {In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM who have exhausted treatment with lenalidomide and bortezomib. The optimal starting dose of pomalidomide is 4 mg given on days 1-21 of each 28-day cycle, while dexamethasone is administered at a dose of 40 mg weekly (reduced to 20 mg for patients aged >75 years). The treatment should continue until evidence of disease progression or unacceptable toxicity. Dose-modification schemes have been established for patients who develop neutropenia, thrombocytopenia and other grade 3-4 adverse events during pomalidomide therapy. Guidance on the prevention and management of infections and venous thromboembolism are provided, based on the available clinical evidence and the experience of panel members. The use of pomalidomide in special populations, such as patients with advanced age, renal impairment or unfavourable cytogenetic features, is also discussed.Leukemia accepted article preview online, 5 February 2014; doi:10.1038/leu.2014.60.},
  author       = {Dimopoulos, M A and Leleu, X and Palumbo, A and Moreau, P and Delforge, M and Cavo, M and Ludwig, H and Morgan, G J and Davies, F E and Sonneveld, P and Schey, S A and Zweegman, S and Hansson, Markus and Weisel, K and Mateos, M V and Facon, T and San Miguel, J F},
  issn         = {1476-5551},
  language     = {eng},
  number       = {8},
  pages        = {1573--1585},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.},
  url          = {http://dx.doi.org/10.1038/leu.2014.60},
  volume       = {28},
  year         = {2014},
}